# Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

> **NCT02955069** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 116 (actual)

## Conditions studied

- Well-differentiated Non-functional NET of Thoracic Origin
- Well-differentiated Non-functional NET of Gastrointestinal Origin
- Well-differentiated Non-functional NET of Pancreatic Origin
- Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

## Interventions

- **DRUG:** PDR001

## Key facts

- **NCT ID:** NCT02955069
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-14
- **Primary completion:** 2018-08-10
- **Final completion:** 2020-05-13
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2021-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955069, "Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02955069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*